We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-1.7%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$170M
AUM Growth
-$2.53M
(-1.5%)
Cap. Flow
+$6.01M
Cap. Flow
% of AUM
3.53%
Top 10 Holdings %
Top 10 Hldgs %
52.61%
Holding
53
New
12
Increased
19
Reduced
9
Closed
7
Top Buys
| 1 |
STRM
Streamline Health Solutions
STRM
|
+$7.38M |
| 2 |
Alkermes
ALKS
|
+$5.2M |
| 3 |
CVS Health
CVS
|
+$4.95M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$3.65M |
| 5 |
Collegium Pharmaceutical
COLL
|
+$3.53M |
Top Sells
| 1 |
Cigna
CI
|
+$12.1M |
| 2 |
United Therapeutics
UTHR
|
+$7.07M |
| 3 |
Labcorp
LH
|
+$5.86M |
| 4 |
Amgen
AMGN
|
+$5.84M |
| 5 |
Merck
MRK
|
+$4.46M |
Sector Composition
| 1 | Healthcare | 96.1% |
| 2 | Consumer Staples | 2.06% |
| 3 | Technology | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lantheus
LNTH
$6.84B
| $14.6M | 8.59% |
208,000
-42,000
| -17% | -$3.18M |
|
|
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
| $10.4M | 6.13% |
685,000
+135,000
| +25% | +$2.18M |
|
3
Pacira BioSciences
PCRX
$1.01B
| $10.4M | 6.09% |
195,000
+20,000
| +11% | +$1.11M |
|
4
Perrigo
PRGO
$1.54B
| $9.09M | 5.34% |
255,000
+55,000
| +28% | +$2.21M |
|
5
Tenet Healthcare
THC
$17.2B
| $9.03M | 5.3% |
175,000
+15,000
| +9% | +$890K |
|
6
Cerus
CERS
$643M
| $8.73M | 5.13% |
2,425,000
+425,000
| +21% | +$2.03M |
|
7
SI-BONE Inc
SIBN
$786M
| $8.03M | 4.72% |
460,000
-75,000
| -14% | -$1.2M |
|
8
AngioDynamics
ANGO
$584M
| $6.65M | 3.9% |
325,000
+5,000
| +2% | +$110K |
|
9
Phreesia
PHR
$673M
| $6.63M | 3.89% |
260,000
+15,000
| +6% | +$374K |
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.02M | 3.53% |
71,000
+41,000
| +137% | +$3.65M |
|
11
Sanofi
SNY
$106B
| $5.89M | 3.46% |
155,000
+60,000
| +63% | +$2.67M |
|
|
STRM
12
DELISTED
Streamline Health Solutions
STRM
| $5.87M | 3.45% |
+328,725
| New | +$7.38M |
|
|
13
Cigna
CI
$75.1B
| $5.55M | 3.26% |
20,000
-43,000
| -68% | -$12.1M |
|
14
Viatris
VTRS
$20.2B
| $5.54M | 3.25% |
650,000
+300,000
| +86% | +$2.95M |
|
15
Bioventus
BVS
$842M
| $5.25M | 3.08% |
750,001
| – | – |
|
|
16
Collegium Pharmaceutical
COLL
$1.18B
| $4.81M | 2.82% |
300,000
+200,000
| +200% | +$3.53M |
|
|
17
CVS Health
CVS
$136B
| $4.77M | 2.8% |
+50,000
| New | +$4.95M |
|
|
18
Alkermes
ALKS
$8.66B
| $4.47M | 2.62% |
+200,000
| New | +$5.2M |
|
19
Jazz Pharmaceuticals
JAZZ
$15.2B
| $4M | 2.35% |
30,000
+5,000
| +20% | +$760K |
|
20
DocGo
DCGO
$63M
| $3.72M | 2.18% |
375,000
+200,000
| +114% | +$1.81M |
|
21
Turning Point Brands
TPB
$1.62B
| $3.5M | 2.06% |
165,000
-25,000
| -13% | -$620K |
|
22
AtriCure
ATRC
$1.8B
| $2.64M | 1.55% |
67,500
-32,500
| -33% | -$1.49M |
|
23
Rigel Pharmaceuticals
RIGL
$771M
| $2.36M | 1.39% |
200,000
| – | – |
|
24
ICU Medical
ICUI
$4.05B
| $2.26M | 1.33% |
15,000
+2,000
| +15% | +$333K |
|
|
25
Merck
MRK
$315B
| $2.15M | 1.26% |
25,000
-50,000
| -67% | -$4.46M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU